Ms. Cox, Chairman and Chief Executive Officer of Humacyte is a seasoned executive who has been a prominent visionary in the healthcare industry. Her illustrious career spans leading large pharmaceutical companies in senior leadership positions. Well known for deep industry insights and an engaging leadership style, Ms. Cox has led global healthcare companies, serving as Chairman of Prism Pharmaceuticals, and as EVP and President of Global Pharmaceuticals at Schering-Plough Corporation, and President, Global Business Management at Pharmacia Corporation (now Pfizer).

Ms. Cox has served as CEO of Humacyte since 2010. Over that time she has successfully and seamlessly shepherded Humacyte from an early research and developmental stage firm to investigating Humacyte’s new technology in late-stage clinical trials (Humacyte entered Phase III clinical trial for its human acellular vessel in 2016). She has been a driving and influential force at the company, bringing deep healthcare knowledge and perspective to prepare Humacyte’s clinical products for commercialization.

Under Ms. Cox’s leadership and guidance, Humacyte has progressed the development and study of technology that addresses critical unmet medical needs for patients suffering from End-Stage Renal Disease and who must rely on dialysis to save their lives. Notably, in 2015, under Ms. Cox’s stewardship -- Humacyte received a monumental $150 million in Series B funding commitments from a global consortium of investors, one of the largest funding rounds in biotechnology to date. The funding is being used for Humacyte’s clinical trials for HUMACYL, and will help to support the company’s research and development work on other significant applications such as peripheral arterial disease, vascular trauma, and vascular reconstruction.

She’s been named six times to FORTUNE Magazine’s list of the “50 Most Powerful Women in Business” and she was named to “Top 10 Women in Biotech” by FierceBiotech in 2012. Additionally, her work has been featured in the Harvard Business Review and in the New York Times bestseller, The Profit Zone.